Latest Sunitinib Stories
By Nicola Fenwick CANCER experts have accused a health watchdog of forcing patients to remortgage their homes to pay for treatments freely available in Europe.
The National Institute for Health and Clinical Excellence, UK has rejected four kidney cancer treatments for use on the National Health Service on grounds that the drugs are not cost effective, according to PharmaTimes.
By Gavin Engelbrecht THE Government?s drugs approval agency warned last night it might not be able to meet a pledge to speed up decision-making on new treatments.
Regarding the drug Sutent which was refused to Mrs Hopkins who dedicated 42 years of her life to the health service, all I can ask is how can we afford to give benefits to some of these immigrants who have never put a single penny into our communities? It seems to me the less you work, the more help you seem to get.
A Leading Welsh cancer specialist has condemned plans to prevent patients with advanced kidney cancer from getting specialised drug treatments.
By David Roberts A SURVEY has revealed more than 1,300 cancer patients nationwide are being denied vital drugs because of a ?postcode lottery? over who gets access to them.
COVENTRY health chiefs are supporting a draft decision to reject four new cancer drugs for patients with advanced kidney cancer. The National Institute for Health and Clinical Excellence (Nice) decided that sunitinib, bevacizumab, sorafenib and Torisel are not a cost-effective use of NHS cash.
By Barry Nelson A CANCER patient who has survived in the past year because of a wonder drug has condemned plans to deny it to other patients because of the cost. Stan Craddock, 63, from Darlington, said he survived the past ten months because of the drug Sutent.
TWO cancer sufferers from Warwickshire have been left angered by a national medical board's decision not to fund a life-lengthening wonder drug. As featured in the Telegraph, Ade Cure, from Wellesbourne, and Colin Howe, from Rugby, are both dying of kidney cancer.
By Barry Nelson NORTH-EAST health bosses say newly referred kidney cancer patients will continue to receive an expensive drug for the time being. The reassurance from the North of England Cancer Network came after Wednesday?s announcement of draft guidance rejecting four new cancer drugs.